When a heart attack begins, a stopwatch starts. With each passing minute heart tissue is deprived of blood, causing it to deteriorate or die. In order to minimize damage to the heart, blood flow must be restored promptly, or the effects can be serious, often even fatal. Research shows that the length of time between when a heart attack starts and when treatment begins is fundamental to improving survival rates. So, what if an alarm sounded at the onset of a heart attack signaling the immediate need for medical attention?
“While survival rates have improved over the last several years, far too many patients still die from heart attacks each year,” says Dan Fintel, MD, cardiologist at Northwestern’s Bluhm Cardiovascular Institute. “If we could identify a heart attack sooner, we may be able to save more lives.”
Northwestern Memorial is among 100 centers nationwide participating in the ALERTS trial examining use of the AngelMed Guardian® implantable device. About the size of a silver dollar, the device monitors heart activity 24 hours a day, seven days a week using a wire inserted in the heart muscle to constantly monitor its electrical activity. When changes such as the heart not getting enough oxygen occur, an antenna on the device sends a signal to a pager the patient carriers, notifying them that a heart attack may be imminent.
“Heart attack symptoms are often misunderstood, causing patients to unknowingly delay treatment,” says Fintel. “This device makes it clear that medical attention is needed, allowing the patient to seek help quickly and providing us a chance to start treatment before a heart attack results in irreversible damage.”
The AngelMed Guardian is designed for patients who have already experienced a heart attack and are at high risk for another heart attack. It is implanted as a pacemaker via a minimally invasive surgical procedure and has the potential to detect a heart attack at its earliest stage.
Interested participants and clinicians should contact Elonia Martin at 312-926-2671 or email@example.com. For more information about the ALERTS Trial, visit the Bluhm Cardiovascular Institute’s Clinical Trial Unit website.